CARRIE BOOTS: Open Payments
NPI 1003012352 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,439 in 51 payments from 23 companies in 2025. Trend: 2023 $2,202 · 2024 $2,141 · 2025 $1,439
Food & beverage: $1,064Consulting: $375
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $455 |
| AstraZeneca Pharmaceuticals LP | 7 | $161 |
| Novartis Pharmaceuticals Corporation | 5 | $97 |
| Merck Sharp & Dohme LLC | 4 | $91 |
| Genentech USA, Inc. | 3 | $67 |
| Eisai Inc. | 3 | $65 |
| JAZZ PHARMACEUTICALS INC. | 2 | $62 |
| Adaptive Biotechnologies Corporation | 2 | $49 |
| Celgene Corporation | 3 | $45 |
| Gilead Sciences, Inc. | 2 | $44 |
Products named: DATROWAY, KEYTRUDA, KISQALI, Lenvima, ZEPZELCA, clonoSEQ, REBLOZYL, Trodelvy.
Industry payments across IN — which companies pay providers there.
